Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD3480 · 6 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | - |
| AZD3480 | DRUG | Capsules 5 mg/day (once a day) for 2 weeks |
| Donepezil | DRUG | - |
| Aripiprazole | DRUG | single dose on day 5 |
| Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin) | DRUG | Cocktail mix which contains the following: CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin) single dose of mix |
| Warfarin | DRUG | Warfarin: single dose on day 6 |
Inclusion Criteria: * Confirmed diagnosis of DSM-IV ADHD * Score of equal or more than 2 on at least six of nine items in at least one of the subscales of the Connor´s Adult ADHD Rating Scale (CAARS-INV) * Score of equal or more than 4 (at least moderate severity) on the Clinical Global Impressions...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 1 | PHASE3 | SPN-812 |
| Axsome Therapeutics, Inc. | AXSM | 3 | PHASE3 | Solriamfetol |
AZD3480 is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for psychiatric and neurological conditions. It has been studied in ADHD, Alzheimer's disease, schizophrenia, and metabolism-related research. It is a Phase 2 clinical candidate and has not been approved for any indication.
AZD3480 has been studied for adult attention-deficit/hyperactivity disorder (ADHD), Alzheimer's disease, schizophrenia, and metabolism-related conditions. It remains investigational and is not approved for any use. Clinical trials have explored its effects in these indications, but no regulatory approval has been granted.
AZD3480 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical trials evaluating AZD3480 in psychiatric and neurological indications.
AZD3480 is in Phase 2 of clinical development. It has completed three Phase 1 drug interaction studies and one Phase 2 exploratory trial in adult ADHD. The drug remains investigational and has not been approved by the FDA or any other regulatory agency.
AZD3480 has been evaluated in completed trials including NCT00692510 (drug interaction with cytochrome P450), NCT00689637 (interaction with warfarin), NCT00689559 (interaction with aripiprazole), and NCT00683462 (Phase 2 trial in adult ADHD). All trials are completed; no active trials are ongoing.
Yes, AZD3480 is also known as TC-1734. The Phase 2 trial NCT00683462 refers to the drug as AZD3480 (TC-1734), confirming they are the same compound. Both names refer to the same investigational small molecule developed by AstraZeneca.